Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder

Neuropsychobiology

Volumn 59, Issue 4, 2009, Pages 227-233

  Amsterdam, Jay D ^a,i   Williams, David ^b   Michelson, David ^c   Adler, Lenard A ^d   Dunner, David L ^e   Nierenberg, Andrew A ^f   Reimherr, Frederick W ^g   Schatzberg, Alan F ^h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e Center for Anxiety and Depression   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ The Science Center Philadelphia   (United States)

Author keywords

Antidepressant drug therapy; Major depressive disorder; Serotonin reuptake inhibitor; Tachyphylaxis; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ATOMOXETINE; BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; PROTRIPTYLINE; S CITALOPRAM; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; OBSERVATIONAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK; TACHYPHYLAXIS; TREATMENT RESPONSE;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; PROPYLAMINES; RECURRENCE; SERTRALINE; TACHYPHYLAXIS; TREATMENT OUTCOME;

EID: 67649445967     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226611     Document Type: Article

References (43)

1. Sharma V:Loss of response to antidepressants and subsequent refractoriness:diagnostic issues in a retrospective case series. J Affect Disord 2001;64:99-106.
2. Fava GF:Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003;64:123-133.
3. Posternak MA, Zimmerman M:Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors:a retrospective study. J Clin Psychiatry 2005;66:705-707.
4. Solomon DAL, Mueller AC, Coryell TI, et al: Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry 2005;66:283-290. (Pubitemid 40476749)
5. Thase ME:Preventing relapse and recurrence of depression:a brief review of therapeutic options. CNS Spectr 2006;11(suppl 15):12-21.
6. Amsterdam JD, Maislin G, Potter L:Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:243-261. (Pubitemid 24102907)
7. Amsterdam JD, Shults J:MAOI safety and efficacy in advanced treatment-resistant depression - a retrospective analysis. J Affect Disord 2005;89:183-188. (Pubitemid 41740846)
8. Leykin Y, Amsterdam JD, DeRubeis RJ, et al: Progressive resistance to SSRI therapy but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol 2007;75:267-276.
9. Zimmerman M, Thongy T:How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. J Clin Psychiatry 2007;68: 1271-1276. 10 Thase ME, Friedman ES, Howland RH:Venlafaxine and treatment-resistant depression. Depress Anxiety 2000;12(suppl 1):55-62. (Pubitemid 47395630)
10. Thase ME, Entsuah AR, Rudolph RL:Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2 001;178:234-241.
11. Reimherr FW, Amsterdam JD, Fawcett J, et al:Optimal length of continuation therapy: a prospective assessment during fluoxetine long-term treatment. Am J Psychiatry 1998; 55:1247-1253.
12. Zajecka JM:Augmentation strategies to increase antidepressant tolerability. J Clin Psychiatry 2007;68:23-27. (Pubitemid 47507834)
13. Thase ME, Rush AJ:Treatment-resistant depression; in Bloom FE, Kupfer DJ, (eds):Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995.
14. Smeraldi E, Zanardi R, Benedetti F, et al: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-511. (Pubitemid 28515526)
15. Pollock BG, Ferrell RE, Mulsant BH, et al: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23:587-590.
16. Jacobs N, Kenis G, Peeters F, et al:Stress-related negative affectivity and genetically altered serotonin transporter function:evidence of synergism in shaping risk of depression. Arch Gen Psychiatry 2006;63: 989-996. (Pubitemid 44330457)
17. Neumeister A, Hu XZ, Luckenbaugh DA, et al:Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry 2006;63:978-986. (Pubitemid 44330456)
18. Zajecka JM:Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61:20-25. (Pubitemid 30131899)
19. Lieb J, Balter A:Antidepressant tachyphylaxis. Med Hypotheses 1984;15:279-291.
20. Nierenberg AA, Feighner JP, Rudolph R, et al:Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423.
21. Nierenberg AA, Papakostas GI, Petersen T, et al:Nortriptyline for treatment-resistant depression. J Clin Psychiatry 2003;64:35-39.
22. Rush AJ, Trivedi MH, Wisniewski SR, et al: Acute and longer-term outcomes in depressed outpatients who required one or several treatment steps:a STAR*D report. Am J Psychiatry 2006;163:1905-1917.
23. First MB, Spitzer RL, Gibbon M, et al:Structured Clinical Interview for Axis I DSM-IV Disorders - Patient Edition. Washington, American Psychiatric Press, 1994.
24. Michelson D, Adler LA, Amsterdam JD, et al: Addition of atomoxetine for depression incompletely responsive to sertraline:a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:582-587. (Pubitemid 46663041)
25. First M, Spitzer R, Gibbon M, et al:Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/P W/ PSY SCREEN). New York, Biometrics Research, New York State Psychiatric Institute, 2001.
26. Williams JB:A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742-747. (Pubitemid 18189914)
27. Maier W, Philipp M:Improving the assessment of depressive states:a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985;18:114-115. (Pubitemid 15137667)
28. Kim DK, Lim SW, Lee S, et al:Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11: 215-219. (Pubitemid 30053421)
29. Yoshida K, Ito K, Sato K, et al:Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:383-386. (Pubitemid 34038069)
30. Murphy GM Jr, Hollander SB, Rodrigues HE, et al:Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61:1163-1169.
31. Cervilla JA, Rivera M, Molina E, et al:The 5HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees:the PREDICT-gene study. Am J Med Genet 2006;141:912-917. (Pubitemid 44905447)
32. Heils A, Teufel A, Petri S, et al:Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-2624. (Pubitemid 26159101)
33. Reimherr FW, Adler LA, Amsterdam JD, et al:Genetic polymorphisms in the treatment of depression:speculations from an augmentation study using atomoxetine (abstract). NCDEU 46th Annu Meet, Boca Raton, 2006.
34. Fava M, Rush AJ, Wisniewski SR, et al:A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163: 1161-1172. (Pubitemid 44464443)
35. McGrath PJ, Stewart JW, Fava M, et al:Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression:a STAR*D report. Am J Psychiatry 2006;163: 1531-1541. (Pubitemid 44465752)
36. Rush AJ, Trivedi MH, Wisniewski SR, et al: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242.
37. Trivedi MH, Rush AJ, Wisniewski SR, et al: STAR*D study team:evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D:implications for clinical practice. Am J Psychiatry 2006;163:28-40.
38. Goldapple K, Segal Z, Garson C, et al:Modulation of cortical-limbic pathways in major depression:treatment specific effects of cognitive behavioral therapy compared to paroxetine. Arch Gen Psychiatry 2004;61:34-41. (Pubitemid 38044639)
39. Bateson AN:Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 2002;8:5-21.
40. Bonavita CD, Bisagno V, Bonelli CG, et al: Tolerance to the sedative effect of lorazepam correlates with a diminution in cortical release and affinity for glutamate. Neuropharmacology 2002;42:619-625. (Pubitemid 34457742)
41. Biggio G, Dazzi L, Biggio F, et al:Molecular mechanisms of tolerance to and withdrawal of GABA(A) receptor modulators. Eur Neuropsychopharmacol 2003;13:411-423. (Pubitemid 37433962)
42. Casey DE:Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am 1993;16:589-610.
43. Simpson GM:Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacology 1997;17:194-201.